Predictive Biomarker Discovery Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Predictive biomarkers are the foundation of precision medicine. The identification of predictive biomarkers is an important scientific component in advancing the drug discovery and development pipeline. With advances in biotechnology, several high-throughput methods have been utilized for predictive biomarker discovery, to elucidate the etiology and molecular mechanisms of cancers.

Creative Biolabs has organized a staff of outstanding scientists who have engaged in predictive biomarker discovery for many years. Our innovative predictive biomarker discovery strategies facilitate the integration of patient-centric multi-omics and clinical data; towards the early identification of novel disease biomarkers. By leveraging the wealth of information that we have on predictive biomarker discovery, we are pleased to help you with your study.

Increasing Demand for Predictive Biomarkers

Support for the development of predictive biomarkers for drug response is wide and varied. These considerations are relevant to many recently developed cancer drugs that target discrete molecular aberrations, which are usually effective on only a subset of patients. The changing pharmacoeconomic environment and the increasing cost of drugs make predictive biomarkers more and more important. One important advantage of predictive biomarkers is the reduction in unnecessary treatment and adverse effects. Identification of predictive biomarkers as a companion diagnostic becomes a more common guideline and general practice. Therefore, there is an increasing need for the discovery of predictive biomarkers to allow patients with responsive diseases to be identified and treated accordingly.

Table 1. Examples of predictive biomarkers for drug response. (La Thangue, 2011)

Biomarker	Cancer type	Drug therapy	Drug target
HER2 (gene amplification)	Breast	Trastuzumab	HER2
Estrogen receptor (protein expression)	Breast	Tamoxifen	Estrogen receptor
BCR–ABL (gene translocation)	Chronic myeloid leukemia	Imatinib, dasatinib, nilotinib	BCR–ABL
EGFR ± KRAS (KRAS mutation)	Colorectal cancer	Cetuximab, panitumumab	EGFR
EGFR (kinase domain mutation)	Non-small-cell lung cancer	Erlotinib, gefitinib	EGFR
PML–RAR (gene translocation)	Acute promyelocytic leukemia	All trans retinoic acid	PML–RAR
BRCA1/2 (mutation)	Breast	Olaparib, veliparib	PARP
BRAF V600E (mutation)	Melanoma	Vemurafenib	BRAF
ALK (rearrangements)	Non-small-cell lung cancer	Crizotinib	ALK

Predictive Biomarkers Discovery Services at Creative Biolabs

Powered by our advanced platforms and experienced technical personnel, Creative Biolabs has perfected our technical pipelines in the discovery of predictive biomarkers. A variety of different high-throughput approaches are available for biomarker discovery, including Single-nucleotide Polymorphism Analysis, transcript profiling by Gene Expression Microarray, and next-generation sequencing (NGS) methods, such as Tumor Mutational Burden (TMB), Neoantigen Load Analysis, Microsatellite Instability (MSI), T Cell Receptor (TCR) Repertoire Sequencing. Through our high-throughput system, functionally relevant cancer biomarkers can be identified, which can then be rationalized in the context of the mechanism of tumor cell killing, and used to support its clinical development.

Creative Biolabs also has developed in silico methodologies to identify predictive biomarkers for a specific type of purpose. Our scientists especially focus on the study of disease-related biomarkers, towards the early identification of novel bio-available markers.

Creative Biolabs Helps You

Discover predictive biomarkers of interest in early phase clinical trials
Rapid disease diagnosis
Prediction of drug resistance and patient response
Development of personalized medicine strategies

With our state-of-the-art technology and industry-leading expertise, Creative Biolabs offers accurate and effective solutions for researchers who are committed to identifying predictive biomarkers. If you are interested in our services, please don't hesitate to contact us for more information and a detailed quote.

References

La Thangue, N.B.; Kerr, D.J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature reviews Clinical oncology. 2011, 8(10):587-96.
Delmar, P.; et al. Innovative methods for the identification of predictive biomarker signatures in oncology: Application to bevacizumab. Contemporary clinical trials communications. 2017, 5:107-15.